NCT06681623View on ClinicalTrials.gov

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

RecruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Interventions
DRUG

Ublituximab

Drug: ublituximab

Trial Locations (1)

02035

RECRUITING

Neurology Center of New England P.C., Foxborough

All Listed Sponsors
lead

Neurology Center of New England P.C.

OTHER